1、 HENDRICKS A J,YOSIPOVITCH G,SHI V Y.Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review[J].J Dermatolog Treat,2021,32(1):19-28. HENDRICKS A J,YOSIPOVITCH G,SHI V Y.Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review[J].J Dermatolog Treat,2021,32(1):19-28.
2、 潘展砚,金城,董达科.外周血嗜酸性粒细胞计数在急性荨麻疹住院患者中的临床意义[J].检验医学与临床,2021,18(15):2169-2172. 潘展砚,金城,董达科.外周血嗜酸性粒细胞计数在急性荨麻疹住院患者中的临床意义[J].检验医学与临床,2021,18(15):2169-2172.
3、 刘钧菲,刘翠华,厉洪江,等.白芍总苷胶囊联合注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗幼年特发性关节炎23例及对T淋巴细胞免疫、Th1/Th2漂移及红细胞沉降率的影响[J].安徽医药,2020,24(2):381-385. 刘钧菲,刘翠华,厉洪江,等.白芍总苷胶囊联合注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗幼年特发性关节炎23例及对T淋巴细胞免疫、Th1/Th2漂移及红细胞沉降率的影响[J].安徽医药,2020,24(2):381-385.
4、 姜静婧,宋红梅.IgE介导的自身免疫及炎症反应的研究进展[J].国际儿科学杂志,2021,48(11):780-784. 姜静婧,宋红梅.IgE介导的自身免疫及炎症反应的研究进展[J].国际儿科学杂志,2021,48(11):780-784.
5、 刘燕婷,李晓强,陈乐,等.白芨散治疗脂溢性皮炎临床观察及对血清IL-4、IL-6、INF-γ水平的影响[J].湖北中医药大学学报,2022,24(1):82-84. 刘燕婷,李晓强,陈乐,等.白芨散治疗脂溢性皮炎临床观察及对血清IL-4、IL-6、INF-γ水平的影响[J].湖北中医药大学学报,2022,24(1):82-84.
6、 ZENG Z W,HUANG J Q,CHEN Y,et al.Acupoint autohemotherapy attenuates atopic dermatitis lesions by regulating Th1/Th2 balance in DNCB-induced BALB/c mice[J].Chin J Integr Med,2022,28(7):612-619. ZENG Z W,HUANG J Q,CHEN Y,et al.Acupoint autohemotherapy attenuates atopic dermatitis lesions by regulating Th1/Th2 balance in DNCB-induced BALB/c mice[J].Chin J Integr Med,2022,28(7):612-619.
7、 REICH K,TEIXEIRA H D,de BRUIN-WELLER M,et al.Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis(AD Up):results from a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2021,397(10290):2169-2181. REICH K,TEIXEIRA H D,de BRUIN-WELLER M,et al.Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis(AD Up):results from a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2021,397(10290):2169-2181.
8、 SIEGELS D,HERATIZADEH A,ABRAHAM S,et al.Systemic treatments in the management of atopic dermatitis:A systematic review and meta-analysis[J].Allergy,2021,76(4):1053-1076. SIEGELS D,HERATIZADEH A,ABRAHAM S,et al.Systemic treatments in the management of atopic dermatitis:A systematic review and meta-analysis[J].Allergy,2021,76(4):1053-1076.
9、 陆晓云,张曾云鸥,肖风丽.上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J].中华皮肤科杂志,2022,55(6):548-551. 陆晓云,张曾云鸥,肖风丽.上皮源性细胞因子白细胞介素33、白细胞介素25和胸腺基质淋巴细胞生成素在特应性皮炎发病机制中的作用[J].中华皮肤科杂志,2022,55(6):548-551.
10、 SAJEDIANFARD S,HANDJANI F,SAKI N,et al.Family dermatology life quality index in patients with pemphigus vulgaris:A cross-sectional study[J].Indian J Dermatol Venereol Leprol,2021,87(3):375-378. SAJEDIANFARD S,HANDJANI F,SAKI N,et al.Family dermatology life quality index in patients with pemphigus vulgaris:A cross-sectional study[J].Indian J Dermatol Venereol Leprol,2021,87(3):375-378.
11、 李妍,徐薇,顾恒,等.阿伐斯汀联合氯雷他定治疗慢性难治性荨麻疹的多中心随机对照研究[J].中华皮肤科杂志,2020,53(5):319-323. 李妍,徐薇,顾恒,等.阿伐斯汀联合氯雷他定治疗慢性难治性荨麻疹的多中心随机对照研究[J].中华皮肤科杂志,2020,53(5):319-323.
12、 顾建青,高翔,孙劲旅,等.度普利尤单抗治疗中重度特应性皮炎初步临床观察[J].中华临床免疫和变态反应杂志,2021,15(4):370-375. 顾建青,高翔,孙劲旅,等.度普利尤单抗治疗中重度特应性皮炎初步临床观察[J].中华临床免疫和变态反应杂志,2021,15(4):370-375.
13、 卢娇. 强脉冲光联合成纤维细胞生长因子治疗激素依赖性皮炎患者经皮水分丢失量的效果研究[J].中国处方药,2022,20(8):142-144. 卢娇. 强脉冲光联合成纤维细胞生长因子治疗激素依赖性皮炎患者经皮水分丢失量的效果研究[J].中国处方药,2022,20(8):142-144.
14、 REICH K,KABASHIMA K,PERIS K,et al.Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis:A randomized clinical trial[J].JAMA Dermatol,2020,156(12):1333-1343. REICH K,KABASHIMA K,PERIS K,et al.Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis:A randomized clinical trial[J].JAMA Dermatol,2020,156(12):1333-1343.
15、 鲁瑾,杨慧,汤璐瑜.贵阳市15家养老机构老年瘙痒性皮肤病发病情况及生活质量[J].中国老年学杂志,2020,40(16):3564-3567. 鲁瑾,杨慧,汤璐瑜.贵阳市15家养老机构老年瘙痒性皮肤病发病情况及生活质量[J].中国老年学杂志,2020,40(16):3564-3567.
16、 KATOH N,OHYA Y,IKEDA M,et al.Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018,The Japanese Society of Allergology,The Japanese Dermatology Association.Japanese guidelines for atopic dermatitis 2020[J].Allergol Int,2020,69(3):356-369. KATOH N,OHYA Y,IKEDA M,et al.Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018,The Japanese Society of Allergology,The Japanese Dermatology Association.Japanese guidelines for atopic dermatitis 2020[J].Allergol Int,2020,69(3):356-369.